Diagnosis and treatment of invasive group a streptococcal infections

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 3, 2008, Pages 289-301

  Steer, Andrew C ^a   Curtis, Nigel ^a   Carapetis, Jonathan R ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Group A streptococcus; Necrotising fasciitis; Sepsis; Streptococcus pyogenes; Toxic shock

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CLINDAMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; IMMUNOGLOBULIN; M PROTEIN; PENICILLIN G; PENICILLIN V; RIFAMPICIN; SUPERANTIGEN;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; CLINICAL FEATURE; CONTROLLED STUDY; CULTURE MEDIUM; DEBRIDEMENT; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; FLUID RESUSCITATION; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE ORGAN FAILURE; NECROTIZING FASCIITIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME;

EID: 77953443091     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.3.289     Document Type: Review

References (129)

1. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in rhe intermountain area of the United States. N Engl J Med 1987;316:421-7
2. Stevens DL. The flesh-eating bacterium: what's next? J Infect Dis 1999;179(Suppl 2):S366-74
3. O'Grady K-A, Kelpie L, Andrews RA, et al. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Aust 2007;186:565-9
4. Carapetis J, Robins-Browne R, Martin D, et al. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 1995;21:1220-7
5. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989;2:285-314
6. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511
7. Hasty DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesins of streptococci. Infect Immun 1992;60:2147-52
8. Horstmann RD, Sievertsen HJ, Leippe M, Fischetti VA. Role of fibrinogen in complement inhibition by streptococcal M protein. Infect Immun 1992;60:5036-41
9. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991;88:8317-21
10. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996;64(2):503-10
11. Curtis N. Invasive group A streptococcal infection. Curr Opin Infect Dis 1996;9:191-2
12. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002;2(3):156-62
13. Curtis N. Kawasaki disease and toxic shock syndrome - at last the etiology is clear? Adv Exp Med Biol 2004;549:191-200
14. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995;8(3):411-26
15. Petersson K, Forsberg G, Walse B. Interplay between superantigens and immunoreceptors. Scand J Immunol 2004;59(4):345-55
16. Proft T, Sriskandan S, Yang L, Fraser JD. Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis 2003;9(10):1211-8
17. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000;13(1):16-34
18. Miethke T, Wahl C, Heeg K, et al. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992;175(1):91-8
19. Stevens DL. Streptococcal toxic shock syndrome. Clin Microbiol Infect 2002;8(3):133-6
20. Katz AR, Morens DM. Severe streptococcal infections in historical perspective. Clin Infect Dis 1992;14(1):298-307
21. Hribalova V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988;108(5):772
22. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987;317:146-9
23. Bartter T, Dascal A, Carroll K, Curley FJ. 'Toxic strep syndrome'. A manifestation of group A streptococcal infection. Arch Intern Med 1988;148(6):1421-4
24. Wheeler MC, Roe MH, Kaplan EL, et al. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA 1991;266:533-7
25. Wong VK, Wright HT Jr. Group A beta-hemolytic streptococci as a cause of bacteremia in children. Am J Dis Child 1988;142:831-3
26. Christie CD, Havens PL, Shapiro ED. Bacteremia with group A streptococci in childhood. Am J Dis Child 1988;142(5):559-61
27. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancer Infect Dis 2005;5(11):685-94
28. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-62
29. Miyairi I, Berlingieri D, Protic J, Belko J. Neonatal invasive group A streptococcal disease: case report and review of the literature. Pediatr Infect Dis J 2004;23(2):161-5
30. Mahieu LM, Holm SE, Goossens HJ, Van Acker KJ. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995;127(6):987-9
31. O'Brien KL, Beall B, Barrett L, et al. Epidemiology of Invasive Group A Streptococcus Disease in the United States, 1995-1999. Clin Infect Dis 2002;35:268-76
32. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352(1):39-47
33. Steer AC, Jenney AJ, Oppedisano F, et al. High burden of invasive beta-haemolytic streptococcal infections in Fiji. Epidemiol Infect 2007;1-7
34. Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 1993;269:384-9
35. Lamagni TL, Efstratiou A, Vuopio-Varkila J, et al. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Eurosurveillance 2005;10(9):179-84
36. Bessen DE, Carapetis JR, Beall B, et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000;182:1109-16
37. Natoli S, Fimiani C, Faglieri N, et al. Toxic shock syndrome due to group C streptococci. A case report. Intensive Care Med 1996;22(9):985-9
38. Wagner JG, Schlievert PM, Assimacopoulos AP, et al. Acute group G streptococcal myositis associated with streptococcal toxic shock syndrome: case report and review. Clin Infect Dis 1996;23:1159-61
39. Sharma M, Khatib R, Fakih M. Clinical characteristics of necrotizing fasciitis caused by group G Streptococcus: case report and review of the literature. Scand J Infect Dis 2002;34(6):468-71
40. Hashikawa S, Iinuma Y, Furushita M, et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol 2004;42:186-92
41. Hirose Y, Yagi K, Honda H, et al. Toxic shock-like syndrome caused by non-group A beta-hemolytic streptococci. Arch Intern Med 1997;157(16):1891-4
42. Korman TM, Boers A, Curtis N, Visvanathan K. Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin. J Clin Microbiol 2004;42(6):2866-9
43. Russell FM, Biribo S, Selvaraj G, et al. As a bacterial culture medium, citrated sheep blood agar is a practical alternative to citrated human blood agar in laboratories of developing countries. J Clin Microbiol 2006;44(9):3346-51
44. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993;269:390-1
45. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996;335:547-54
46. Chelsom J, Halstensen A, Hagal T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994;344:1111-5
47. Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977;134(1):52-7
48. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997;103(1):18-24
49. Ward RG, Walsh MS. Necrotizing fasciitis: 10 years' experience in a district general hospital. Br J Surg 1991;78:488-9
50. Wall DB, de Virgilio C, Black S, Klein SR. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg 2000;179(1):17-21
51. Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000;105(5):E60
52. Brogan TV, Nizet V, Waldhausen JH, et al. Group A streptococcal necrotizing fasciitis complicating primary varicella a series of fourteen patients. Pediatr Infect Dis J 1995;14(7):588-94
53. Brothers TE, Tagge DU, Stutley JE, et al. Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J Am Coll Surg 1998;187(4):416-21
54. Zittergruen M, Grose C. Magnetic resonance imaging for early diagnosis of necrotizing fasciitis. Pediatr Emerg Care 1993;9(1):26-8
55. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. Am J Roentgenol 1998;170(3):615-20
56. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984;310(26):1689-93
57. Wong CH, Wang YS. The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis 2005;18(2):101-6
58. Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32(7):1535-41
59. Kevy SV, Lowe BA. Streptococcal pneumonia and empyema in childhood. N Engl J Med 1961;264:738-43
60. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. The WHO Young Infants Study Group. Pediatr Infect Dis J 1999;18(10 Suppl):S17-22
61. Shetty AK, Frankel LR, Maldonado Y, et al. Group A streptococcal meningitis: report of a case and review of literature since 1976. Pediatr Emerg Care 2001;17(6):430-4
62. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992;14:2-11
63. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995;1:69-78
64. Reingold AL, Hargrett NT, Shands KN, et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 1982;96(6 Pt 2):875-80
65. Doctor A, Harper MB, Fleisher GR. Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics 1995;96(3 Pt 1):428-33
66. Falcone PA, Pricolo VE, Edstrom LE. Necrotizing fasciitis as a complication of chickenpox. Clin Pediatr (Phila) 1988;27(7):339-43
67. Vugia DJ, Peterson CL, Meyers HB, et al. Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J 1996;15:146-50
68. Wilson GJ, Talkington DF, Gruber W, et al. Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin Infect Dis 1995;20(5):1333-8
69. Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999;103:783-90
70. Cowan MR, Primm PA, Scott SM, et al. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med 1994;23(4):818-22
71. Bradley JS, Schlievert PM, Sample TG Jr. Streptococcal toxic shock-like syndrome as a complication of varicella. Pediatr Infect Dis J 1991;10(1):77-9
72. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Varicella-associated group A streptococcal disease in Alberta, Canada 2000-2002. Clin Infect Dis 2005;40:1055-7
73. Rimailho A, Riou B, Richard C, Auzepy P. Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs. J Infect Dis 1987;155(1):143-6
74. Brun-Buisson CJ, Saada M, Trunet P, et al. Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1985;290(6484):1786
75. Krige JE, Spence RA, Potter PC, Terblanche J. Necrotising fasciitis after diflunisal for minor injury. Lancet 1985;2(8469-70):1432-3
76. Curtis N. Non-steroidal anti-inflammatory drugs may predispose to invasive group A streptococcal infections. Arch Dis Child 1996;75(6):547
77. Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995;21(4):977-80
78. Stevens DL. The toxic shock syndromes. Infect Dis Clin North Am 1996;10(4):727-46
79. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003;85-A(8):1454-60
80. Bilton BD, Zibari GB, McMillan RW, et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64(5):397-400
81. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005;37(3):166-72
82. Muller MP, McGeer A, Low DE; Ontario Group A Streptococcal Study. Successful outcome in six patients treated conservatively for suspected necrotizing fasciitis (NF) due to group A streptococcus (GAS) [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; December 2001
83. Catena F, La Donna M, Ansaloni L, et al. Necrotizing fasciitis: a dramatic surgical emergency. Eur J Emerg Med 2004;11(1):44-8
84. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8
85. Mascini EM, Jansze M, Schouls LM, et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001;18:395-8
86. Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997;40(2):275-7
87. Herbert S, Barry P, Novick RP. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect Immun 2001;69(5):2996-3003
88. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981;67(5):1249-56
89. Craig WA, Vogelman B. The postantibiotic effect. Ann Intern Med 1987;106(6):900-2
90. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003;96(10):968-73
91. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18(12):1096-100
92. Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 2001;7(5):354-61
93. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;(1):CD001090
94. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996;64:5395-8
95. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996;156:3057-64
96. Andersson U, Chauvet JM, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes J Immunol Methods 1994;175:201-13
97. Sriskandan S, Ferguson M, Elliot V, et al. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006;58(1):117-24
98. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40
99. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-7
100. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324(23):1633-9
101. Cockerill FR 3rd. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children [comment). Pediatrics 1998;101:136-40
102. Huang YC, Hsueh PR, Lin TY, et al. A family cluster of streptococcal toxic shock syndrome in children: clinical implication and epidemiological investigation. Pediatrics 2001;107(5):1181-3
103. Schwartz B, Elliott JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992;15(2):277-84
104. Gamba MA, Martinelli M, Schaad HJ, et al. Familial transmission of a serious disease - producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997;24(6):1118-21
105. Stromberg A, Romanus V, Burman LG. Outbreak of group A streprococcal bacteremia in Sweden: an epidemiologic and clinical study. J Infect Dis 1991;164(3):595-8
106. Auerbach SB, Schwartz B, Williams D, et al. Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. Arch Intern Med 1992;152(5):1017-22
107. Prevention of Invasive Group ASIWP. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention [erratum appears in Clin Infect Dis 2003;36(2):243]. Clin Infect Dis 2002;35:950-9
108. Dahl PR, Perniciaro C, Holmkvist KA, et al. Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J Am Acad Dermatol 2002;47(4):489-92
109. Zerr DM, Rubens CE. NSAIDS and necrotizing fasciitis. Pediatr Infect Dis J 1999;18(8):724-5
110. Ford LM, Waksman J. Necrotizing fasciitis during primary varicella. Pediatrics 2000;105(6):1372-3; author reply 3-5
111. Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001;107(5):1108-15
112. Forbes N, Rankin AP. Necrotizing fasciitis and non steroidal anti-inflammatory drugs: a case series and review of the literature. NZ Med J 2001;114(1124):3-6
113. Carapetis JR. Current issues in managing group A streptococcal infections. Adv Exp Med Biol 2004;549:185-90
114. Kotloff KL, Dale JB. Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004;23(8):765-6
115. Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002;70(4):2171-7
116. Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004;292(6):709-15
117. Batzloff M, Yan H, Davies M, Hartas J, Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004;119(Suppl):104-7
118. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diptheria toxoid: contribution of J8-and diptheria toxoid-specific antibodies to protection. J Infect Dis 2003;187:1598-608
119. Kurlan R, Kaplan EL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinician. Pediatrics 2004;113:883-6
120. Swedo SE, Leonard HL, Rapoport JL. The Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infection (PANDAS): separating fact from fiction. Pediatrics 2004;113:907-11
121. Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998;27(1):150-7
122. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000-2002). J Clin Microbiol 2005;43:1678-83
123. Eriksson BK, Norgren M, McGregor K, et al. Group A streptococcal infections in Sweden: a comparative study of invasive and noninvasive infections and analysis of dominant T28 emm28 isolates. Clin Infect Dis 2003;37(9):1189-93
124. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998;27(6):1428-36
125. Kristensen B, Schonheyder HC. A 13-year survey of bacteraemia due to beta-haemolytic streptococci in a Danish county. J Med Microbiol 1995;43(1):63-7
126. Moses AE, Goldberg S, Korenman Z, et al. Invasive group A streptococcal infections, Israel. Emerg Infect Dis 2002;8(4):421-6
127. Lamagni TL, Duckworth G, Emery M, et al. The changing epidemiology of invasive Streptococcus pyogenes infections in England and Wales: 1991-2001. 15th Lancefield International Symposium on Streptococci and Streptococcal Diseases. Goa, India; 2002. p. O1.4
128. Norton R, Smith HV, Wood N, et al. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 2004;119(Suppl):148-51
129. Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr 1991;119:123-8